Science
Ventrio® clinical data
Set-up:
20 participants between 23-72 years old (8 male and 12 female) were advised to take 2 capsules of Ventrio® daily during a period of 4 weeks. No other products (or food) with an influence on the stool were allowed during the entire follow-up period.
Clinical scores (Bristol stool, flatulence, bloating, stomach ache, wellbeing and frequence) were documented daily and stool samples were taken before study start and at week 2 and 4 for metagenomics 16S profiling analysis to assess the gut microbiome.
Results:
|
All participants with diarrhea (Bristol score > 4 at day 0) showed significant improvement within 24-48h after Ventrio® intake.
|
Participants with flatulence showed significant improvement within 24h after Ventrio® intake.
|
Bloating and stomach ache normalized within 1-2 weeks after Ventrio® intake. In 4 participants an increase in bloating was noticed at week 3 which resolved when reducing the dose to 1 capsule a day.
|
|
|
Also the daily stool frequency normalized in all patients with hypermotility after Ventrio® intake.
An average net promotor score of 7/10 was noted and 73% of participants with clinical discomfort noticed improvement.
The metagenomics analysis revealed 985 different bacterial species (see example of Sankey visualization below) inthe stool of the 20 participants.
|
Lactobacillus rhamnosus and plantarum were not detectable before study start and significantly increased in the stool over time after Ventrio® intake.  |
Detection of Streptococcus species significantly reduced after Ventrio® intake.  |
Conclusion:
In conclusion, a daily intake of 2 capsules of Ventrio® for 2 weeks resulted in clinical and microbiological improvement in humans with gastro-intestinal discomfort.
For long term use it is advised to reduce the dose to 1 capsule per day after 2 weeks.
